FI914147A0 - Stabiliserade fasta kemiska kompositioner. - Google Patents

Stabiliserade fasta kemiska kompositioner.

Info

Publication number
FI914147A0
FI914147A0 FI914147A FI914147A FI914147A0 FI 914147 A0 FI914147 A0 FI 914147A0 FI 914147 A FI914147 A FI 914147A FI 914147 A FI914147 A FI 914147A FI 914147 A0 FI914147 A0 FI 914147A0
Authority
FI
Finland
Prior art keywords
water soluble
stabilizer
chemical
composer
fasta
Prior art date
Application number
FI914147A
Other languages
English (en)
Other versions
FI104361B (fi
FI914147A (fi
Inventor
Haan Pieter De
Der Ven Cornelus Josephus Van
Original Assignee
Akzo Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akzo Nv filed Critical Akzo Nv
Publication of FI914147A0 publication Critical patent/FI914147A0/fi
Publication of FI914147A publication Critical patent/FI914147A/fi
Priority to FI991387A priority Critical patent/FI991387A/fi
Application granted granted Critical
Publication of FI104361B publication Critical patent/FI104361B/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Developing Agents For Electrophotography (AREA)
  • Lubricants (AREA)
FI914147A 1990-09-13 1991-09-03 Menetelmä granulointimenetelmän karkeuden lisäämiseksi sekä emäksisen yhdisteen käyttö stabilointiaineena granulointiprosessissa FI104361B (fi)

Priority Applications (1)

Application Number Priority Date Filing Date Title
FI991387A FI991387A (fi) 1990-09-13 1999-06-17 Stabiloituja kiinteitä kemiallisia koostumuksia

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US58185990A 1990-09-13 1990-09-13
US58185990 1990-09-13

Publications (3)

Publication Number Publication Date
FI914147A0 true FI914147A0 (fi) 1991-09-03
FI914147A FI914147A (fi) 1992-03-14
FI104361B FI104361B (fi) 2000-01-14

Family

ID=24326864

Family Applications (1)

Application Number Title Priority Date Filing Date
FI914147A FI104361B (fi) 1990-09-13 1991-09-03 Menetelmä granulointimenetelmän karkeuden lisäämiseksi sekä emäksisen yhdisteen käyttö stabilointiaineena granulointiprosessissa

Country Status (14)

Country Link
EP (1) EP0475482B1 (fi)
JP (1) JP3153577B2 (fi)
KR (1) KR100196209B1 (fi)
AT (1) ATE112491T1 (fi)
AU (1) AU643920B2 (fi)
CA (1) CA2049811C (fi)
DE (1) DE69104453T2 (fi)
DK (1) DK0475482T3 (fi)
ES (1) ES2064887T3 (fi)
FI (1) FI104361B (fi)
IE (1) IE65274B1 (fi)
NZ (1) NZ239753A (fi)
PT (1) PT98955B (fi)
ZA (1) ZA916661B (fi)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0865789T3 (da) * 1993-03-26 2005-07-18 Franciscus Wilhelmus He Merkus Farmaceutiske præparater til intranasal administration af dihydroergotamin
NZ501321A (en) * 1997-03-26 2001-04-27 Franciscus W Nasal Melatonin composition
GB0001621D0 (en) 2000-01-26 2000-03-15 Astrazeneca Ab Pharmaceutical compositions
US6691057B2 (en) 2001-02-26 2004-02-10 L.U.M. Gesellschaft Fur Labor- Umweltdiagnostic & Medizintechnik Mbh Method and device for accelerated stability analysis
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
CA2491665A1 (fr) * 2004-12-24 2006-06-24 Louis Cartilier Formulation de comprime pour liberation soutenue de principe actif
CA2810295C (en) 2006-05-04 2017-11-14 Boehringer Ingelheim International Gmbh A polymeric form of 1-((4-methyl-quinazolin-2-yl)methyl)-3-7-(2-butyn-1-yl)-8-(3-(r)-aminopiperidin-1-yl)xanthine
PE20110235A1 (es) 2006-05-04 2011-04-14 Boehringer Ingelheim Int Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
PE20140960A1 (es) 2008-04-03 2014-08-15 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
KR20200118243A (ko) 2008-08-06 2020-10-14 베링거 인겔하임 인터내셔날 게엠베하 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
AU2009331471B2 (en) 2008-12-23 2015-09-03 Boehringer Ingelheim International Gmbh Salt forms of organic compound
AR074990A1 (es) 2009-01-07 2011-03-02 Boehringer Ingelheim Int Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina
CA2782179C (en) 2009-11-27 2020-06-23 Boehringer Ingelheim International Gmbh Treatment of genotyped diabetic patients with dpp-iv inhibitors such as linagliptin
ES2935300T3 (es) 2010-05-05 2023-03-03 Boehringer Ingelheim Int Combiterapia
ES2953123T3 (es) 2010-06-24 2023-11-08 Boehringer Ingelheim Int Terapia para la diabetes
US9034883B2 (en) 2010-11-15 2015-05-19 Boehringer Ingelheim International Gmbh Vasoprotective and cardioprotective antidiabetic therapy
EP2731947B1 (en) 2011-07-15 2019-01-16 Boehringer Ingelheim International GmbH Substituted dimeric quinazoline derivative, its preparation and its use in pharmaceutical compositions for the treatment of type i and ii diabetes
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
EP3685839A1 (en) 2012-05-14 2020-07-29 Boehringer Ingelheim International GmbH Linagliptin for use in the treatment of albuminuria and kidney related diseases
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
US9526728B2 (en) 2014-02-28 2016-12-27 Boehringer Ingelheim International Gmbh Medical use of a DPP-4 inhibitor
RU2609198C1 (ru) * 2016-01-25 2017-01-30 Закрытое Акционерное Общество "БИОКОМ" Твердая лекарственная форма имипрамина немедленного высвобождения и способ ее получения
BR112018072401A2 (pt) 2016-06-10 2019-02-19 Boehringer Ingelheim International Gmbh combinações de linagliptina e metformina
KR102416406B1 (ko) * 2019-09-24 2022-07-04 주식회사 종근당 티카그렐러의 산 부가염을 포함하는 안정화된 약학 조성물

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2554736A (en) 1951-05-29 Tertiary aminoalkyl-iminodibenzyls
US2018410A (en) 1933-12-11 1935-10-22 Victor Chemical Works Dentifrice preparation
US2287699A (en) 1940-02-15 1942-06-23 Monsanto Chemicals Stabilized dicalcium phosphate
US3012852A (en) 1956-06-06 1961-12-12 Monsanto Chemicals Stabilized calcium phosphates and process therefor
DE1277222B (de) 1965-12-22 1968-09-12 Knapsack Ag Verfahren zur Stabilisierung von Dicalciumphosphatdihydrat
NL129434C (fi) 1966-03-12
US4128641A (en) 1975-07-31 1978-12-05 Hzi Research Center Inc. Tetracyclic psychotropic drug
DE2648061C2 (de) 1976-10-23 1982-11-04 Hoechst Ag, 6000 Frankfurt Verfahren zum Stabilisieren von Di-calciumhydrogenphosphatdihydrat
DE2741513A1 (de) 1977-09-15 1979-03-22 Benckiser Gmbh Joh A Verfahren zum stabilisieren von calciumhydrogenphosphat-dihydrat gegen hydrolyse
IE52274B1 (en) 1980-12-12 1987-09-02 Stauffer Chemical Co A process of compacting fine particles of calcium phosphate and the compacts obtained thereby
SE8103843L (sv) * 1981-06-18 1982-12-19 Astra Laekemedel Ab Farmaceutisk mixtur
US4743450A (en) 1987-02-24 1988-05-10 Warner-Lambert Company Stabilized compositions
US5004651A (en) 1989-01-24 1991-04-02 Abbott Laboratories Stabilizing system for solid dosage forms
GB8920693D0 (en) * 1989-09-13 1989-10-25 Nicholas Kiwi Pty Ltd Non-effervescent ibuprofen compositions

Also Published As

Publication number Publication date
CA2049811C (en) 2002-11-05
IE65274B1 (en) 1995-10-18
ATE112491T1 (de) 1994-10-15
FI104361B (fi) 2000-01-14
PT98955B (pt) 1999-02-26
DE69104453D1 (de) 1994-11-10
ES2064887T3 (es) 1995-02-01
AU8341691A (en) 1992-03-19
JPH0578236A (ja) 1993-03-30
PT98955A (pt) 1992-08-31
FI914147A (fi) 1992-03-14
JP3153577B2 (ja) 2001-04-09
KR920005978A (ko) 1992-04-27
AU643920B2 (en) 1993-11-25
NZ239753A (en) 1992-10-28
DE69104453T2 (de) 1995-03-16
CA2049811A1 (en) 1992-03-14
ZA916661B (en) 1992-06-24
EP0475482A1 (en) 1992-03-18
EP0475482B1 (en) 1994-10-05
DK0475482T3 (da) 1995-04-03
KR100196209B1 (ko) 1999-06-15
IE913054A1 (en) 1992-02-25

Similar Documents

Publication Publication Date Title
FI914147A0 (fi) Stabiliserade fasta kemiska kompositioner.
KR0136279B1 (ko) 일정수분을 함유하는 서방형 제제
NO176203C (no) Fremgangsmåte for fremstilling av ibuprofentabletter med forsinket frigjöring
ATE37882T1 (de) Cephalosporinverbindungen, verfahren zu ihrer herstellung und sie enthaltende pharmazeutische praeparate.
ES483767A1 (es) Procedimiento para producir n-arilsulfonil-l-argininamidas
US5350582A (en) Stable formulation of enalapril salt, a process for the preparation thereof and the use thereof
KR910002670B1 (ko) 아모술랄롤 하이드로클로라이드 지속성 제제의 제조방법
EP0264259B1 (en) Stabilized pharmaceutical compositions
IL113011A (en) R-mandelic acid salt of (2s,3s)-3- (2-methoxybenzylamino)-2- phenylpiperidine
JPS5581596A (en) Composition for determining creatine kinase
BR9609964A (pt) Formulação sólida estável de sal de enalaprila e processo para preparação da mesma
WO1990009170A3 (fr) Agents pour le diagnostic et le traitement des melanomes, derives halogenes aromatiques utilisables comme de tels agents et leur preparation
HUT53664A (en) Process for producing enzyme inhibiting amino acid derivatives and pharmaceutical compositions comprising such compounds as active ingredient
MY137475A (en) Chemical compounds.
ES505865A0 (es) Un procedimiento mejorado para producir un preparado antimicrobiano de d-7(&-(4-hidroxi-6-metilnicotinamido)-4-hidroxi- fenilacetamido)-3-(1-metiltetrazol-5-il) tiometil-a3-cefem-4-carboxilato de sodio.
NO177484C (no) Fremgangsmåte for fremstilling av et farmasöytisk preparat i form av myke kapsler
ES516694A0 (es) Procedimiento de preparacion de derivados de la 4-fenil quinazolina.
CA2015714A1 (en) Stable aqueous formulations of fluorescent whitening agents
AU3750085A (en) Preparation of 3-phenyl alanines derivatives
ATE41769T1 (de) Immunwirksame verbindungen.
KR850008280A (ko) 니페디핀 제제물의 제조방법
IL95166A0 (en) Renin-inhibiting amino oligohydroxy derivatives
ATE33837T1 (de) Azolylmethylcycloacetale, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel.
NO178137C (no) Fremgangsmåte for fremstilling av et polyprenylholdig farmasöytisk preparat i form av harde kapsler
SE8202254L (sv) 2,4-dioxacyklohexanon-derivat

Legal Events

Date Code Title Description
PC Transfer of assignment of patent

Owner name: N.V. ORGANON

Free format text: N.V. ORGANON

MA Patent expired